Supporting Prostate Cancer Focal Therapy: A Multidisciplinary International Consensus Of Experts ("ice")

Prostate cancer is a common malignancy among men, and the current screening, imaging and sampling approaches aim to detect early-stage, organ-confined disease. In such scenario, focal prostate cancer therapy currently relies on the index lesion concept as the dominant lesion that drives the disease natural history. Focal therapy demands the essential imaging and sampling techniques to strategically locate and qualify the disease, but, despite advances in technology, prostate imaging and biopsy have several limitations that need to be overcome if focal therapy is to be developed further. The I Prostate Cancer Focal Treatment International Symposium was convened to foster discussion on this topic that sits at the crossroads of multiple disciplines (Urology, Pathology, Radiology, Radiation Oncology and Medical Oncology) all of which were represented for this comprehensive multidisciplinary review of the current literature. © 2014 Informa UK Ltd.1726671Stamen, T.A., Freiha, F.S., McNeal, J.E., Localized prostate cancer relationship of tumor volume to clinical significance fotr treatment of prostate cacer (1993) Cancer, 71, pp. 933-938Ahmed, H., The index lesion and the origin of the prostate cancer (2009) N Eng J Med, 361, pp. 1704-1706Karavitakis, M., Winkler, M., Abel, P., Histological characteristics of the index lesion in whole mountain radical prostatectomy specimens: Implications for focal therapy (2001) Prostate Cancer Prostatic Dis, 14, pp. 46-52Van Der Kwast, T.H., Amin, M.B., Billis, A., International society of urological pathology (isup) consensus conference on handling and staging of rp specimens working group 2: T2 substaging and prostate cancer volume (2011) Mod Pathol, 24, pp. 16-25Liu, W., Laitinen, S., Khan, S., Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer (2009) Nat Med, 15, pp. 559-565De La Rosete Ahmed, H., Barentsz, J., Focal therapy in prostate cancer-report from a consensus panel (2012) J Endourol, 24, pp. 775-780Billis, A., Meirelles, L.R., Freitas, L.L., Prostate total tumor extent versus index tumor extent-which is predictive of biochemical recurrence following radical prostatectomy (2013) J Urol, 189, pp. 99-104Karavitakis, M., Ahmed, H.U., Abel, P.D., Margin status after laparoscopic radical prostatectomy and the index lesion: Implications for preoperative evaluation of tumor focallity in prostate cancer (2012) J Endourol, 26, pp. 503-508Ukimura, O., Abreu, A.L.C., Gill, I.S., Imagem visibility to enhance targeting precision and spatial mapping biopsy for focal therapy of prostate cancer (2013) BJU Int, 111, pp. E354-E365Rosenkrantz, A.B., Deng, F.M., Kim, S., Prostate cancer: Multiparametric MRI for index lesion localization-A multiplereader study (2012) AJR Am J Roentgenol, 199, pp. 830-837Simon, R.J.B., Hashim, U.A., Richard, G.H., The index lesion and focal therapy an analysis of the pathological characteristics of prostate cancer (2010) BJU Int, 106, pp. 1607-1611Haffner, M.C., Mosbruger, T., Esopi, D.M., Tracking the clonal origin of lethal prostate cancer (2013) J Clin Invest, 123, pp. 4918-4922Dickinsons, L., Ahmed, H.U., Kirkham, A.P., A multicenter prospective development study using high intensity focused ultrasound for localized prostate cancer (2013) Contemp Clin Trials, 36, pp. 68-80Epstein, J.I., Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens (2011) J Urol, 186, pp. 790-797Eichelberger, L.E., Koch, M.O., Daggy, J.K., Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer (2003) Am J Clin Pathol, 120, pp. 386-389Mouraviev, V., Villers, A., Bostwick, D.G., Understanding the pathological features of focality, grade and tumour volume of earlystage prostate cancer as a foundation for parenchyma-spearing prostate cancer therapies: Active surveillance and focal targeted therapy (2011) BJU Int, 108, pp. 1074-1085Noguchi, M., Stamey, T.A., McNeal, J.E., Nolley, R., Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: Lack of significance of secondary cancers (2003) Journal of Urology, 170, pp. 459-463Billis, A., Magna, L.A., Ferreira, U., Correlation between tumor extent in radical prostatectomies and preoperative PSA, histological grade, surgical margins, and extraprostatic extension: Application of a new practical method for tumor extent evaluation (2003) Int Braz J Urol, 29, pp. 113-119Turkbey, B., Pinto, P.A., Choyke, P.L., Imaging techniques for prostate cancer: Implications for focal therapy (2009) Nat Rev Urol, 6, pp. 191-203Turkbey, B., Mani, H., Shah, V., Multiparametric 3T prostate magnetic resonance imaging to detect cancer: Histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds (2011) J Urol, 186, pp. 1818-1824Guzzo, T.J., Resnick, M.J., Canter, D.J., Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance (2012) Urol Oncol, 30, pp. 301-305Shukla-Dave, A., Hricak, H., Akin, O., Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer (2012) BJU Int, 109, pp. 1315-1322Turkbey, B., Mani, H., Aras, O., Prostate cancer: Can multiparametric MR imaging help identify patients who are candidates for active surveillance (2013) Radiology, 268, pp. 144-152Reis, L.O., Mendonça, G., Menezes, O., Core biopsy length impacts gleason upgrading on radical prostatectomy (2013) Urology, 82, pp. S286Scattoni, V., Zlotta, A., Montironi, R., Schulman, C., Rigatti, P., Montorsi, F., Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: A critical analysis of the literature (2007) European Urology, 52 (5), pp. 1309-1322. , DOI 10.1016/j.eururo.2007.08.006, PII S030228380700989XFuganti, P.E., Tobias-Machado, M., Pinto, M.A., Twelve core biopsy versus six systematic sextant biopsies (2002) Braz J Urol, 28, pp. 207-213Lawrentschuk, N., Haider, M.A., Daljeet, N., Prostatic evasive anterior tumours: The role of magnetic resonance imaging (2010) BJU Int, 105, pp. 1231-1236Barqawi, A.B., Rove, K.O., Gholizadeh, S., The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer (2011) J Urol, 186, pp. 80-85Franiel, T., Stephan, C., Erbersdobler, A., Areas suspicious for prostate cancer: Mr-guided biopsy in patients with at least one transrectal us-guided biopsy with a negative finding- multiparametric mr imaging for detection and biopsy planning (2011) Radiology, 259, pp. 162-172Hambrock, T., Somford, D.M., Hoeks, C., Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen (2010) J Urol, 183, pp. 520-527Turkbey, B., Shah, V.P., Pang, Y., Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images (2011) Radiology, 258, pp. 488-495Villers, A., Puech, P., Mouton, D., Leroy, X., Ballereau, C., Lemaitre, L., Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: Correlation with radical prostatectomy findings (2006) Journal of Urology, 176 (6), pp. 2432-2437. , DOI 10.1016/j.juro.2006.08.007, PII S0022534706019756Puech, P., Potiron, E., Lemaitre, L., Dynamic contrast-enhancedmagnetic resonance imaging evaluation of intraprostatic prostate cancer: Correlation with radical prostatectomy specimens (2009) Urology, 74, pp. 1094-1099Lemaitre, L., Puech, P., Poncelet, E., Dynamic contrast-enhanced MRI of anterior prostate cancer: Morphometric assessment and correlation with radical prostatectomy findings (2009) Eur Radiol, 19, pp. 470-480Puech, P., Huglo, D., Petyt, G., Imaging of organ-confined prostate cancer: Functional ultrasound, mri and pet/computed tomography (2009) Curr Opin Urol, 19, pp. 168-176Kilinç, R., Doluoglu, O.G., Sakman, B., The Correlation between diffusion-weighted imaging and histopathological evaluation of 356 prostate biopsy sites in patients with prostatic diseases (2012) ISRN Urol, 2012, p. 252846Salomon, G., Schiffmann, J., Real-Time elastography for the detection of prostate cancer (2014) Curr Urol Rep, 15, p. 392Simmons, L.A., Ahmed, H.U., Moore, C.M., The picture study-prostate imaging (multi-parametric mri and prostate histoscanning-) compared to transperineal ultrasound guided biopsy for significant prostate cancer risk evaluation (2014) Contemp Clin Trials, 37, pp. 69-8

Prognostic factors in de novo metastatic renal cell carcinoma : A report from the latin american renal cancer group

Altres ajuts: Janssen Biotech, Merck, Pharmacyclics, Incyte, Taiho Pharmaceutical.PURPOSE To assess the effect of clinical and pathological variables on cancer-specific and overall survival (OS) in de novo metastatic patients from a collaborative of primarily Latin American countries. PATIENTS AND METHODS Of 4,060 patients with renal cell carcinoma diagnosed between 1990 and 2015, a total of 530 (14.5%) had metastasis at clinical presentation. Relationships between clinical and pathological parameters and treatment-related outcomes were analyzed by Cox regression and the log-rank method. RESULTS Of 530 patients, 184 (90.6%) had died of renal cell carcinoma. The median OS of the entire cohort was 24 months. American Society of Anesthesiology classification 3-4 (hazard ratio [HR]: 1.64), perirenal fat invasion (HR: 2.02), and ≥ 2 metastatic organ sites (HR: 2.19) were independent prognostic factors for 5-year OS in multivariable analyses. We created a risk group stratification with these variables: no adverse risk factors (favorable group), median OS not reached; one adverse factor (intermediate group), median OS 33 months (HR: 2.04); and two or three adverse factors (poor risk group), median OS 14 months (HR: 3.58). CONCLUSION Our study defines novel prognostic factors that are relevant to a Latin American cohort. With external validation, these easily discerned clinical variables can be used to offer prognostic information across low- and middle-income countries